THE LONG AND THE SHORT OF IT: WHAT'S NEXT FOR LONG-ACTING DRUGS

Conference Reports for NATAP

Conference on Retroviruses
and Opportunistic Infections
Boston USA
March 8-11, 2020


THE LONG AND THE SHORT OF IT: WHAT'S NEXT FOR LONG-ACTING DRUGS

	Themed Discussion ++ CROI 2020 Reported by Jules Levin http://www.croiwebcasts.org/console/player/44857?mediaType=slideVideo& --------------------- in session: THERAPEUTIC INTERVENTIONS FOR HIV TREATMENT AND ERADICATION CABOTEGRAVIR + RILPIVIRINE EVERY 2 MONTHS IS NONINFERIOR TO MONTHLY: ATLAS-2M STUDY (ABSTRACT 34) Edgar Turner Overton http://www.croiwebcasts.org/console/player/44585?mediaType=slideVideo& poster - Every-2-Month Maintenance CAB + RPV Noninferior to Monthly Dosing for 48 Weeks - (03/09/20) --------------------------- LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV TREATMENT: FLAIR WEEK 96 RESULTS Chloe Orkin http://www.croiwebcasts.org/console/player/44902?mediaType=slideVideo& poster - LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV TREATMENT: FLAIR WEEK 96 RESULTS - (03/11/20) ----------------------------- Islatravir Metabolic Outcomes in a Phase 2b Trial of Treatment-Naïve Adults with HIV-1 - (03/09/20) WEEKLY ORAL ISLATRAVIR PROVIDES EFFECTIVE PEP AGAINST IV CHALLENGE WITH SIVMAC251 - (03/11/20) Tolerability, Safety, and Efficacy of Islatravir (MK-8591) at Doses of 0.25 to 2.25 mg QD, in Combination With Doravirine and Lamivudine Through 24 Weeks in Treatment-Naïve AdultsWith HIV-1 Infection.....http://www.natap.org/2019/IAS/IAS_15.htm Long-Acting MK-8591 at IAS 2019, , New ART for Treatment, PrEP....http://www.natap.org/2019/IAS/IAS_67.htm MK-8591 Potency and PK Provide High Inhibitory Quotients at Low Doses QD and QW http://www.natap.org/2019/CROI/croi_46.htm ------------------------------- DOSE-RESPONSE RELATIONSHIP OF SUBCUTANEOUS LONG-ACTING HIV CAPSID INHIBITOR GS-6207 (ABSTRACT 469) Eric Daar http://www.croiwebcasts.org/console/player/44860?mediaType=slideVideo& ABSENCE OF GS-6207 PHENOTYPIC RESISTANCE IN HIV Gag CLEAVAGE SITE AND OTHER MUTANTS (03/16/20) PK, Food Effect, and Safety of Oral GS-6207, a Novel HIV-1 Capsid Inhibitor (03/16/20) -------------------------------- CABOTEGRAVIR AND RILPIVIRINE PK FOLLOWING LONG-ACTING HIV TREATMENT DISCONTINUATION (ABSTRACT 466) Susan Ford http://www.croiwebcasts.org/console/player/44858?mediaType=slideVideo& CABOTEGRAVIR PHARMACOKINETIC TAIL IN PREGNANCY AND NEONATAL OUTCOMES (03/17/20)